Disease targeting therapies in patients with Eisenmenger syndrome: Response to treatment and long-term efficiency

International Journal of Cardiology

Volumn 167, Issue 3, 2013, Pages 840-847

  Diller, Gerhard Paul ^a,b   Alonso Gonzalez, Rafael ^a   Dimopoulos, Konstantinos ^a,b   Alvarez Barredo, Maria ^a   Koo, Chiehyang ^a   Kempny, Aleksander ^a   Harries, Carl ^a   Parfitt, Lisa ^a   Uebing, Anselm S ^a   Swan, Lorna ^a   Marino, Philip S ^a,b   Wort, Stephen J ^a,b   Gatzoulis, Michael A ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

6 minute walk test distance; Eisenmenger syndrome; Functional class; Pulmonary arterial hypertension; Therapy

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EISENMENGER COMPLEX; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PATIENT SAFETY; PHYSICAL CAPACITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TISSUE OXYGENATION; UNSPECIFIED SIDE EFFECT;

6-MINUTE WALK TEST DISTANCE; EISENMENGER SYNDROME; FUNCTIONAL CLASS; PULMONARY ARTERIAL HYPERTENSION; THERAPY;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; EISENMENGER COMPLEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880924617     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.02.007     Document Type: Article

References (40)

1. P. Moons, L. Bovijn, W. Budts, A. Belmans, and M. Gewillig Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in belgium Circulation 122 2010 2264 2272
2. Grown-up congenital heart (guch) disease: Current needs and provision of service for adolescents and adults with congenital heart disease in the UK Heart 88 Suppl. 1 2002 i1 i14
3. C.L. Webb, K.J. Jenkins, and P.P. Karpawich Collaborative care for adults with congenital heart disease Circulation 105 2002 2318 2323
4. Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC) ESC guidelines for the management of grown-up congenital heart disease (new version 2010) Eur Heart J 31 2010 2915 2957
5. G.P. Diller, K. Dimopoulos, and D. Okonko Exercise intolerance in adult congenital heart disease: Comparative severity, correlates, and prognostic implication Circulation 112 2005 828 835
6. K. Dimopoulos, R. Inuzuka, and S. Goletto Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension Circulation 121 2010 20 25
7. L. Kidd, D.J. Driscoll, and W.M. Gersony Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects Circulation 87 1993 138 151
8. P.M. Steele, V. Fuster, M. Cohen, D.G. Ritter, and D.C. McGoon Isolated atrial septal defect with pulmonary vascular obstructive disease - long-term follow-up and prediction of outcome after surgical correction Circulation 76 1987 1037 1042
9. V. Eisenmenger Die angeborenen defekte der kammerscheidewände des herzens Z Klin Med 32 1897 1 28
10. G.P. Diller, and M.A. Gatzoulis Pulmonary vascular disease in adults with congenital heart disease Circulation 115 2007 1039 1050
11. R.K. Kumar, and J. Sandoval Advanced pulmonary vascular disease: the Eisenmenger syndrome Cardiol Young 19 2009 622 626
12. H.W. Farber, and J. Loscalzo Pulmonary arterial hypertension N Engl J Med 351 2004 1655 1665
13. M. Beghetti, and N. Galie Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension J Am Coll Cardiol 53 2009 733 740
14. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
15. W.E. Hopkins, L.L. Ochoa, G.W. Richardson, and E.P. Trulock Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome J Heart Lung Transplant 15 1996 100 105
16. M.A. Gatzoulis, P. Rogers, and W. Li Safety and tolerability of bosentan in adults with Eisenmenger physiology Int J Cardiol 98 2005 147 151
17. N. Galie, M. Beghetti, and M.A. Gatzoulis Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 2006 48 54
18. N. Galie, A. Torbicki, and R. Barst Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the european society of cardiology Eur Heart J 25 2004 2243 2278
19. S. Rich Primary pulmonary hypertension: executive summary from the world symposium on primary pulmonary hypertension 1998 Evian WHO
20. Ats statement: Guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
21. R development core team R: a language and environment for statistical computing, Vienna, Austria 2006 3-900051-07-0 http://www.Rproject.Org
22. D.D. Christensen, M.E. McConnell, W.M. Book, and W.T. Mahle Initial experience with bosentan therapy in patients with the Eisenmenger syndrome Am J Cardiol 94 2004 261 263
23. S.C. Apostolopoulou, A. Manginas, D.V. Cokkinos, and S. Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart 93 2007 350 354
24. H. Brun, E. Thaulow, P.M. Fredriksen, and H. Holmstrom Treatment of patients with Eisenmenger's syndrome with bosentan Cardiol Young 17 2007 288 294
25. M. D'Alto, C.D. Vizza, and E. Romeo Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect Heart 93 2007 621 625
26. G.P. Diller, K. Dimopoulos, and M.G. Kaya Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease Heart 93 2007 974 976
27. M.G. Duffels, J.C. Vis, and R.L. van Loon Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol 134 2009 378 383
28. I. Schulze-Neick, N. Gilbert, and R. Ewert Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy Am Heart J 150 2005 716
29. R.L. van Loon, E.S. Hoendermis, and M.G. Duffels Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 154 2007 776 782
30. M.A. Gatzoulis, M. Beghetti, and N. Galie Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the breathe-5 open-label extension study Int J Cardiol 127 2008 27 32
31. E.M. Chau, K.Y. Fan, and W.H. Chow Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension Int J Cardiol 120 2007 301 305
32. N. Garg, M.K. Sharma, and N. Sinha Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship Int J Cardiol 120 2007 306 313
33. T.P. Singh, M. Rohit, A. Grover, S. Malhotra, and R. Vijayvergiya A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension Am Heart J 151 2006 [851 e851-855]
34. S.M. Fernandes, J.W. Newburger, and P. Lang Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology Am J Cardiol 91 2003 632 635
35. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
36. O. Trojnarska, and K. Plaskota Therapeutic methods used in patients with Eisenmenger syndrome Cardiol J 16 2009 500 506
37. G. Roul, P. Germain, and P. Bareiss Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J 136 1998 449 457
38. A.E. Lammers, G.P. Diller, D. Odendaal, S. Tailor, G. Derrick, and S.G. Haworth Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension Arch Dis Child 96 2011 141 147
39. M.J. Schuuring, B.J. Bouma, and R. Cordina Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease Int J Cardiol 164 2013 106 110
40. Y. Mitani, H. Ohashi, S. Takabayashi, H. Shimpo, and Y. Komada Acute effect of sildenafil on hypoxemic patients (excluding those with Eisenmenger syndrome) with incurable congenital heart disease and disturbed pulmonary vasculature in the mid-term follow-up Int J Cardiol 146 2011 273 274